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Abstract
Background: Mounting evidence has indicated that ABI3 (ABI family member 3) function as a tumor suppressor
gene, although the molecular mechanism by which ABI3 acts remains largely unknown.
Methods: The present study investigated ABI3 expression in a large panel of benign and malignant thyroid tumors
and explored a correlation between the expression of ABI3 and its potential partner ABI3-binding protein (ABI3BP).
We next explored the biological effects of ABI3 ectopic expression in thyroid and colon carcinoma cell lines, in
which its expression was reduced or absent.
Results: We not only observed that ABI3 expression is reduced or lost in most carcinomas but also that there is a
positive correlation between ABI3 and ABI3BP expression. Ectopic expression of ABI3 was sufficient to lead to a
lower transforming activity, reduced tumor in vitro growth properties, suppressed in vitro anchorage-independent
growth and in vivo tumor formation while, cellular senescence increased. These responses were accompanied by
the up-regulation of the cell cycle inhibitor p21 WAF1 and reduced ERK phosphorylation and E2F1 expression.
Conclusions: Our result links ABI3 to the pathogenesis and progression of some cancers and suggests that ABI3 or
its pathway might have interest as therapeutic target. These results also suggest that the pathways through which
ABI3 works should be further characterized.
Background
The ABL-Interactors (ABI) proteins were initially identi-
fied as binding partners of c-ABL tyrosine kinase, a
non-receptor tyrosine kinase whose activation results in
cell growth, cell transformation and cytoskeletal reorga-
nization. It has been suggested that the ABI1 (ABI
family member 1) and ABI2 (ABI family member 2) act
as tumor suppressor genes [1,2].
ABI3 (ABI family member 3) is the third member of
ABI protein family that, similar to ABI1 and ABI2, is
involved in membrane ruffling and lamellipodia forma-
tion, which suggest the involvement of ABI3 in cell
motility [3,4].
It has been shown that ABI3 expression is lost in inva-
sive cancer cell lines, despite its ubiquitous expression in
normal tissues [4]. In addition, ectopic expression of
ABI3 in metastatic cell lines caused a marked reduction
in cell motility and exhibited significant reduction in
tumor metastatic potential in vivo [3]. Moreover, over-
expression of ABI3 potently blocked PDGF-stimulated
membrane ruffling in mammalian cells [5]. Although
these reports indicate that ABI3 loss may play a role in
the pathogenesis and/or progression of certain cancers,
the precise function of ABI3 in human cancer and the
potential signaling pathway and downstream effectors of
ABI3 remain unclear.
A yeast two-hybrid system with the SH3 domain of
ABI3 as the bait protein was used in order to identify
novel components of ABI3 signaling pathways. ABI3BP
(ABI3Binding Protein) was originally identified as an
SH3 domain-binding molecule of ABI3 [4].
We previously described that ABI3BP expression is
reduced in malignant thyroid samples, compared to nor-
mal thyroid and benign lesions [6-8]. Furthermore, we
demonstrated that ectopic expression of ABI3BP
decreased tumor growth properties in vitro and in vivo,
while induced senescence [8]. Other studies have shown
that ABI3BP was also associated with pathogenesis of
lung cancers by virtue of its reduced expression in all
lung cell lines and lung primary tumors [9]. The authors
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also demonstrated that ABI3BP is potentially associated
with pathogenesis of colon, ovary and thyroid, as its
expression was reduced in primary tumors compared to
paired normal samples [9].
Our hypothesis is that, similar to ABI3BP, ABI3
expression might be reduced in thyroid carcinomas and
possibly plays a functional role in the pathogenesis and/
or progression of thyroid tumors as well as other
cancers.
To test this hypothesis, we investigated the expression of
ABI3 in thyroid benign and malignant lesions. We found a
decreased expression of ABI3 in thyroid carcinomas. We
next explored the biological role of ABI3 in thyroid and
colon carcinoma cells. We showed that ABI3 suppressed
the in vitro and in vivo transformation, induced senes-
cence and inhibited the oncogenic signaling. These find-
ings demonstrate the tumor suppressing activity of ABI3
and suggest that it may be a target for therapy.
Methods
Tissue samples
A total of 81 thyroid tissue specimens obtained from
patients undergoing thyroid surgery for thyroid disease at
Hospital São Paulo, Federal University of São Paulo, Brazil,
were used for this study. Samples were frozen immediately
after surgical biopsy and stored at -80°C. The samples
included 7 normal thyroid tissues, 21 follicular thyroid
adenomas, 14 Hürthle cell adenomas, 15 follicular thyroid
carcinomas, 6 Hürthle cell carcinomas and 18 papillary
thyroid carcinomas. All tissue samples were obtained with
informed consent according to established Human Studies
Protocols at Federal University of São Paulo. The study of
patient materials was conducted according to the princi-
ples expressed in the Declaration of Helsinki.
RNA extraction, cDNA synthesis and quantitative PCR
(qPCR)
To investigate the level of ABI3 expression in thyroid
tumors, total RNA and cDNA synthesis was performed
as previously described [10]. An aliquot of cDNA was
used in 20 μl PCR reactions containing TaqMan univer-
sal PCR master mix, 10 μM of each specific primer
and FAM-labeled probes for the target gene (ABI3)
and VIC-labeled probe as the reference gene (S8)
(TaqMan®Gene Assays on Demand; Applied Biosystems,
Foster City, CA). Gene expression was normalized to the
average of S8 expression and relative expression was cal-
culated as described earlier [11,12].
Correlation of ABI3 and ABI3BP expression in thyroid
tumors
The level of ABI3 expression was correlated with the
level of ABI3BP, which was previously investigated in
this set of samples [8].
Cell Culture
A follicular thyroid carcinoma cell line (WRO) and a
colon cancer-derived HT-29 cell line (ARO) [13] were
grown in DMEM (Invitrogen Corp., Carlsbad, CA) sup-
plemented with 10% FBS (Invitrogen Corp.), 100 units/
mL of penicillin and 100 μg/mL streptomycin in a
humidified incubator containing 5% CO2 at 37°C
[14,15].
Generation of stable tranfected clones Expressing of ABI3
Plasmid encoding the full-length cDNA of human ABI3
was kindly donated by Dr. Satoru Matsuda (Nagoya Uni-
versity School of Medicine, Nagoya, Japan). To establish
cell lines expressing ABI3, 10 μg of DNA construct were
transfected into WRO and ARO cells by electroporation
using a Gene Pulser II (Bio-Rad Laboratories Inc.,
Hercules, CA). ARO and WRO cells transfected with
pcDNA3.1 vector were used as the negative controls.
Clones were isolated after 3 weeks of selection with G418
(800 μg/mL). At least six G418-resistant clones from each
transfection were isolated, expanded, maintained on G418
(400 μg/mL) and tested for ABI3 expression by qPCR. To
this end, total RNA extracted from each clone was used
for cDNA synthesis as described [8]. An aliquot of cDNA
was used in a 20 μL PCR reaction containing SYBR Green
PCR Master Mix (Applied Biosystems) and 200 nM of
each primer for target or reference genes. qPCR was per-
formed in triplicates and the threshold cycle (Ct) was aver-
aged (SD ≤1). Primer sequences for ABI3 and S8 (internal
control) were as follows: ABI3 sense 5’-CAGGTG-
GAAGCCCGTGTAAG-3’ and antisense 5`-AGTGGC-
TAAGGTGCCGATCTC-3’, yielding a product of 89 bp;
S8 sense 5’-TGAAAGGAAAAAGAATGCCAAAA-3’ and
antisense 5’-CACTGTCCCGGCCTTGAA-3’, yielding a
product of 96 bp. Gene expression was normalized to the
average of S8 and relative expression was calculated as
described [11,12]. For each cell line, two independently
isolated clones that expressed ABI3 at similar levels and
two pcDNA3.1 clones were used for further in vitro and in
vivo experiments.
Transformation assay
About 5 × 106 WRO cells were transfected with 10 μg
of the ABI3 DNA construct as described above. Control
plates were transfected with pcDNA3.1. After 3 weeks
of selection with G418 (800 μg/mL), cells were fixed in
10% acetic acid and 10% of methanol and stained with
1% crystal violet. G418-selected colonies were counted.
Each experiment was performed in triplicate.
Proliferation Assay
Stably transfected clones for ARO and WRO were ana-
lyzed with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT) assay as described [8,16].
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In brief, 2 × 104 cells were seeded in 35-mm plates on
day 0. Cell growth was measured from day 1 to 5 by
adding 0.5 mg/mL of MTT (Sigma-Aldrich, St. Louis,
MO) to the medium at 37°C for 3 hours. The medium
was removed and purple formazan crystals were dis-
solved by adding acid isopropanol. The absorbance of
the supernatant was measured at 560 nm.
Quantification of apoptotic cells by annexin-V labeling
To test whether ectopic expression of ABI3 induces apop-
tosis, 2 × 104 cells were seeded in 35-mm plates and dou-
ble-stained with Annexin V and Nexin 7-AAD according
to the manufacturer’s recommendations (Guava Nexin
method; Guava Technologies). Cell-associated fluores-
cence was analyzed by the Guava PCA flow cytometer
(Guava Technologies). Results are expressed as the per-
centage of apoptotic positive cells. Both early apoptotic
(annexin V-positive) and late apoptotic (annexin V- and
7 AAD-positive) cells were included in the analysis.
Experiments were performed in quintuplicates.
Cell viability assay
ARO Cells (2 × 104) were seeded in 35-mm plates. Cells
were mixed with Guava ViaCount Reagent and allowed
to stain for 10 minutes (Guava Technologies, Hayward,
CA). Viable cells were quantified using a Guava Personal
Analyzer (PCA) flow cytometer (Guava Technologies)
following the manufacturer’s specifications. Experiments
were performed in quintuplicates.
Cell cycle analysis
ARO cells (2 × 105) were seeded in 35-mm dishes. After
synchronization of the cells by serum starvation for 24
hours, cells were replaced with DMEM medium supple-
mented with 10% FBS for 24 hours. Cells were fixed in
70% ethanol for 1 hour, labeled with Guava Cell Cycle
Assay reagent and analyzed using Guava PCA flow cyt-
ometer (Guava Technologies), according to manufac-
turer’s recommendations. Experiments were performed
in quintuplicates.
Expression of p21WAF1 and E2F1 by qPCR
The transcript levels of p21WAF1 and E2F1 were tested
in stably expressing ABI3 ARO and WRO cells and con-
trols, as described [8].
Western blot analysis
Western blot analysis was performed as described [8].
Briefly, membranes were blocked and incubated over-
night at 4°C with anti-phospho-ERK (pERK; dilution
1:1000), anti-phospho-AKT (pAKT; dilution 1:400) and
anti-a- Tubulin (dilution 1:1000). Detection was carried
out using the SuperSignal West Pico chemiluminescent
substrate (Pierce, Rockford, IL, USA).
Cellular senescence
Senescence-associated (SA) b-gal staining was per-
formed as described [17]. Briefly, ARO and WRO cells
(2 × 104) were seeded in 35-mm plates. Cells were
washed twice with PBS, fixed for 15 minutes and stained
with 1 mg/mL 5-bromo-4-chloro-3-inolyl-b-D-galacto-
side (X-gal) in buffer (dimethyformamide, 40 mM citric
acid/sodium phosphate pH 6.0, 5 mM potassium ferro-
cyanide, 5 mM potassium ferricyanide, 150 mM NaCl
and 2 mM MgCl2). Cells were incubated at 37°C in 5%
CO2 for 18 hours and washed twice with PBS. Cells
were examined using a light microscope and counted in
5 optical fields (100×). Data represents mean of an
experiment performed in quintuplicates.
Matrigel invasion assay
Cell invasion was analyzed using BioCoat Matrigel Inva-
sion Chamber according to the manufacturer’s recom-
mendation (Becton Dickinson, Bedford, MA). WRO cell
clones were added to the invasion or control chambers
at a density of 2.5 × 104 and, after 24 hours, cells
remaining above the insert membrane were removed by
gentle scraping with a sterile cotton swab. FBS was used
as chemoattractant. Cells that had invaded through the
Matrigel to the bottom of the insert were fixed and
stained with rapid panoptic LB (Laborclin, Brazil) and
mounted. Cells were examined using a light microscope
and counted in 3 optical fields (100×). Experimental and
control groups were performed in triplicates. The per-
centage of invasion cells was determined by the mean of
cells invading through Matrigel insert membrane divided
by the mean of cells migrating through control insert
membrane X100.
Cell Migration from spheroids
Because high migration capacity might be correlated
with cell spreading and metastasis in vivo, migration
from spheroids was assayed as previously described [8].
Briefly, spheroids were prepared by seeding WRO cells
in DMEM supplemented with 10% FBS, onto 35-mm
tissue culture dishes coated with 0.75% Noble agar.
Cells were cultured until spheroids were formed and
single spheroids were placed at the center of each well
of a 24-well plate. At least 12 single spheroids from
each selected clone were cultured. The area covered by
cells spreading out from the spheroid was measured
every 24 hours for a period of 6 days. The areas of
spheroids were calculated as described [8].
Anchorage-independent growth
Anchorage-independent growth was assessed by a dou-
ble-layer soft agar assay. Initially, 60-mm dishes were
layered with 0.5% agar and 1× complete medium. Next,
ARO cells (1.5 × 104) were suspended in 1× complete
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medium and 0.35% agar and seeded in triplicate over a
bottom layer of solidified agar. The dishes were incu-
bated at 37°C in 5% CO2. After 3 weeks, colonies greater
than 20 μm in diameter were counted. Colony forma-
tion rate was calculated as percentage of total seeded
cells. Two independent experiments were performed.
Nude mouse xenograft model
Four to five week old male athymic nude (nu/nu) mice
were maintained according to the guidelines of the Divi-
sion of Animal Resources at the Federal University of
São Paulo. ARO stable cell clones were suspended in
sterile PBS to 2 × 106/200 μL and injected subcuta-
neously into the flank of mice. Mice were then moni-
tored biweekly during three weeks. Tumor volume was
calculated by the rotational ellipsoid formula: V = A ×
B2/2 (A = axial diameter; B = rotational diameter).
Tumor tissues were collected and embedded in paraffin
for conventional histology or were stored at -80°C.
Statistical analysis
The relative expression values were log transformed before
the application of statistical analysis. Pearson correlation
coefficient was used to verify the correlation between ABI3
and ABI3BP expression. In vitro results were log trans-
formed and analyzed by a Student’s t test. In vivo results
were analyzed by the Wilcoxon test. Significance is pre-
sented as p value of <0.05 (*), < 0.01 (**) and < 0.001 (***).
Results
ABI3 expression is reduced in malignant thyroid lesions
To test the possibility that ABI3 expression is associated
with thyroid tumor malignancy, we examined mRNA
expression in a panel of thyroid tumors specimens and
normal thyroid. As demonstrated by qPCR, ABI3 expres-
sion was reduced in a high percentage of thyroid carcino-
mas while it was expressed in most of benign lesions and
normal thyroid (p≤0.001; Figure 1A). Since we previously
investigated the level of ABI3BP in the aforementioned set
of samples [8], we next correlated the expression of ABI3
with the expression observed for ABI3BP. We found a
medium positive correlation between reduced expression
of ABI3 and ABI3BP (r = 0.346; p = 0.019; Figure 1B).
However, a large positive correlation was observed in
malignant lesions (r = 0.564; p = 0.003; Figure 1B). These
findings and those reported from two-hybrid system sug-
gest that ABI3 and ABI3BP may act through a common
signaling pathway, although biological evidences are still
needed to demonstrate this hypothesis.
Ectopic expression of ABI3 in human carcinoma cell lines
To investigate a functional role of ABI3 in cancer devel-
opment, ABI3 expression was tested in a panel of cell
lines derived from human cancers. A thyroid follicular
cell line (WRO) and a colon cancer cell line (ARO),
which did not express or expressed at very low levels,
were chosen (Figure 1C). A construct expressing ABI3
and an empty vector (control) were transfected into
ARO and WRO cell lines. Seven transfected clones from
each cell line were subsequently tested by qPCR. Two
clones with similar level of ABI3 expression and two
clones from control group were chosen for in vitro and
in vivo studies (p < 0.01; Figure 1C).
Expression of ABI3 suppresses focus formation
To determine the effects of the ABI3 on transformation
of human cancer cells we first determined the effects of
ABI3 on cells growth in a focus formation assay. WRO
cells were stably transfected with vector expressing
ABI3. Control transfections were also performed with
empty vetor. G418-selected colonies were counted after
two weeks. WRO cells transfected with empty vector
formed numerous foci (32.70 foci/μg of plasmid DNA).
In contrast, ectopic expression of ABI3 reduced the
number of colonies formed (0.63 foci/μg of plasmid
DNA) (p < 0.001; Figure 1D). This finding suggests that
ABI3 strong inhibited foci formation.
The ectopic expression of ABI3 reduces cell proliferation
To confirm the effects of the ABI3 on malignant trans-
formation, we next examined the effects of ectopic
expression of ABI3 in growth rate. ABI3 induced a
growth inhibitory effect in the two cell lines as assessed
by MTT assays, mainly at day 5 (Figure 2A). The data
represents the mean ± SD of two experiments per-
formed in triplicates.
ABI3 expression increases the percentage of cells in G0/
G1 phase and reduces cell viability but did not induce
apoptosis on carcinoma cells
The ability of ABI3 to inhibit cell growth could be due
to the cell cycle arrest and/or apoptosis. Therefore we
investigated the effect of ABI3 on apoptosis. Although
we observed a trend toward increased apoptosis in
WRO cells expressing ABI3 when compared to control
cells, the growth attenuation was, however, not accom-
panied by a corresponding increase in apoptotic cells
(Figure 2B). The ABI3-induced growth suppression in
was further studied by flow cytometric analysis, which
revealed a decrease in cell viability (Figure 2C) and cell
cycle arrest at the G0/G1 phase (p < 0.05, Figure 2D).
ABI3 induces the expression of p21WAF1 and reduces E2F1
expression and phosphorylation of ERK
Since p21WAF1 inhibit and E2F1 promotes cell cycle pro-
gression, we tested the transcripts levels of expression of
p21WAF1 and E2F1 following ABI3 expression by quanti-
tative PCR. Stable expression of ABI3 in WRO cells
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Figure 1 Status of ABI3 expression in thyroid tumors and in carcinomas cell lines. (A) ABI3 expression is reduced in most thyroid
malignant tumors (p < 0.001). (B) A positive correlation was observed between levels of ABI3 and ABI3BP expression in the panel of thyroid
samples, mainly in malignant tumors. (C) ABI3 expression in control cells (cells transfected with empty vector) or clones expressing ABI3 (two of
each cell line). (D) ABI3 ectopic expression reduced focus formation. The data represents the mean ± SD of the experiment performed in
triplicates. FTA, Follicular thyroid adenomas; HCA, Hürthle cell adenomas; FTC, follicular thyroid carcinomas; HCC, Hürthle cell carcinomas; PTC,
papillary thyroid carcinomas. *p <0.05, **p < 0.01, ***p≤ 0.001.
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induced p21WAF1 while reduced E2F1 expression at days
3 and 5 post-seeding (p < 0.05; Figure 3A).
Although at lower levels, the expression of p21WAF1
was induced and E2F1 was reduced in ARO cells
expressing ABI3. We next tested phosphorylation of
ERK, which is known to play a pivotal role in cell prolif-
eration. We observed a decrease of ERK phosphorylation
in ABI3-expressing WRO cells compared to control
cells. Two clones from each group are shown indepen-
dently (Figure 3B). No effect was observed in AKT
phosphorylation (data not shown).
ABI3 induces senescence in carcinoma cells
The number of b-Gal positive cells was higher in ARO
and WRO cells expressing ABI3 at days 3 and 5 post-
seeding (Figure 4A and 4B). Representative results are
Figure 2 ABI3 ectopic expression reduced cell proliferation, cell viability and arrested cells in G0/G1 phase. (A) Growth of cells is
suppressed following ABI3 expression, mainly in WRO cell line. (B) The percentage of apoptotic cells was not significantly altered in cell lines
expressing ABI3, compared to control cells. (C) ABI3 expression reduced cell viability in ARO cells, mainly at day 5 where a more evident effect
was observed in the proliferation assay. (D) ABI3 expression increased the percentage of cells in G0-G1 at the expense of G2-M phase. Black bars
correspond to control clones (n = 2) and white bars correspond to ABI3 expressing clones (n = 2). *p < 0.05 and *** p < 0.001.
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Figure 3 ABI3 induced p21WAF1 expression while reducing ERK phosphorylation and E2F1 expression in carcinoma cell lines. (A. two
first panels - two upper panels) An increase in p21WAF1 and decrease in E2F1 expression was observed following ABI3 ectopic expression. Black
bars correspond to control cells and white bars correspond to ABI3 expressing cells. Graphs show mean ± SD of two clones for each
transfectants. (B. third panel-bottom) ABI3 ectopic expression decreases phosphorylated ERK (p-ERK) in WRO cells. Results from two selected
clones are show. C1 and C2 (controls clones) and ABI3 1 and ABI3 2 (clones expressing ABI3). a-Tubulin was used as internal control. *p < 0.05.
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shown on Figure 4C and 4D. As predicted from cell
proliferation and cell cycle assays, the effect was higher
in WRO cells (p < 0.01) than in ARO cells (p < 0.05).
ABI3 expression effects on cells migration
Given that ABI3 was previously associated with a
marked reduction in cell motility, we here tested using
spheroid assay. Expression of ABI3 reduced cell migra-
tion and invasion of WRO cells (Figure 5A and 5B),
although it was not considered statistically significant.
ARO cells did not form spheroids.
ABI3 reduces tumor growth in nude mice
ARO cell line was selected for in vivo assay based on the
fact that ARO cells form large tumors in nude mice
[18], while WRO form smaller tumors with a long latent
period. ARO cells expressing ABI3 did not form tumors
in nude mice (n = 3) or formed a very small tumor
(0.65 ± 1.17 cm3; n = 5). In contrast, control mice had
extensive tumors (3.62 ± 2.84 cm3; n = 8; Figure 6A).
The results are graphically represented as mean of
tumor volume (p = 0.027; Figure 6B). Tumors were pro-
cessed for routine histology and immunohistochemical
analysis. H&E staining revealed no histological differ-
ences among the tumors. Neither lung nor lymph node
metastases were found in any mice.
ABI3 affects anchorage-independent cell growth
Since WRO cells had a very low colony-forming effi-
ciency in agar, ARO cells were selected for its ability to
Figure 4 ABI3 ectopic expression induced senescence in carcinoma cell lines. The percentage of b-galactosidase positive cells was higher
in ARO (A) and WRO (B) cells expressing ABI3 than in control cells. Representative results illustrate increased senescence-associated
b-galactosidase (SA-b-gal) staining in ARO (C) and WRO (D) cells following ABI3 expression on days 3 and 5. *p < 0.05 and **p < 0.01.
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growth in soft agar [18]. Following ABI3 expression, a
significant reduction of the ability of the cells to grow in
semi-solid media was observed (p < 0.05; Figure 6C).
Discussion
We have previously shown that ABI3BP expression is
lost in most malignant carcinomas. We also provided
evidence that ectopic expression of ABI3BP in ABI3BP-
deficient carcinoma cell lines inhibited in vitro and
in vivo cell growth [8]. Based on our previous findings
[6,8] and on the fact that ABI3BP was originally
described as an ABI3-SH3-binding protein isolated by
yeast two-hybrid technique [19], we investigated the
expression of ABI3 in thyroid lesions.
Figure 5 Effect of ABI3 expression in invasion and migration. (A) WRO cells expressing ABI3 had a lower ability to migrate. The graphs
display the mean ± SD of at least 12 spheroids of each clone. (B) The percentage of invasive cells through the Matrigel assay was lower in WRO
cells expressing ABI3. Black bars correspond to control clones (n = 2) and white bars correspond to ABI3 expressing clones (n = 2).
Figure 6 ABI3 reduced tumor formation in nude mice and the ability to growth in semi-solid medium. (A) Representative animals that
received either control cells (left panel) or cells expressing ABI3 (right panel) are shown. The arrows pointed out the formed tumors. (B)
Tumorigenicity experiments are summarized in the graph showing mean ± SD of the volume of tumors after inoculation of ARO cells. (C) The
percentage of colony formation in soft agar is significantly decreased in ARO cells expressing ABI3 in comparison with control cells. Experiments
were performed in triplicates. *p < 0.05.
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In this study, we observed that ABI3 expression is lost or
reduced in most malignant samples, compared to benign
thyroid samples. Since both genes had similar patterns of
expression, we subsequently investigated whether the expres-
sion of ABI3 and ABI3BP correlated in thyroid samples. We
observed a positive correlation between ABI3 and ABI3BP
expression, which was more evident in malignant lesions.
Our findings, in association with the fact that ABI3
expression is frequently lost in invasive cancer cell lines,
and that ABI3 re-expression markedly inhibited cell
motility and significantly reduced the formation of
tumor metastasis in vivo [3], suggest that ABI3 loss of
expression may play an important role in the pathogen-
esis and/or progression of several tumors subtypes.
Herein, we sought to investigate the consequences of
stable expression of ABI3 on diverse steps of carcino-
genesis including proliferation, transformation, survival,
migration, and invasion in vitro and in vivo. To this
end, we stably transfected ABI3 into a thyroid and a
colon carcinoma cell lines [13].
We first demonstrated that ABI3 ectopic expression
reduced cell transformation and suppressed proliferation
of carcinoma cell lines, mainly in a follicular thyroid
carcinoma cell line. The undetectable basal expression
and high fold induction of ABI3 in the follicular thyroid
carcinoma cell line could provide a potential explanation
for the observed inhibitory effects of ABI3 on the cell
proliferation. The different genetic background may also
be responsible for the phenotypic differences.
Moreover, ABI3 expression was able to delay cell cycle
progression and reduce cell viability at significant levels.
Additionally, we found that ABI3 expression induces
senescence, determined by positive results of SA-b-gal
staining, which is a specific cellular senescence marker.
Even though it is not completely understood in detail
how ABI3 promotes cell cycle arrest, reduces prolifera-
tion and induces senescence, our findings indicate that
the ABI3-induced response was mediated by an increase
in p21WAF1 expression, and down regulation of E2F1
expression.
Interestingly, p21WAF1 is a major player in cell cycle
control. Various mechanisms exist to regulate the levels
of p21WAF1. Although tumor suppressor p53 is a major
transcription factor involved in the regulation of
p21WAF1, other factors including TGFb, p73, SP1, Rac1,
Rho, are known to induce the expression of p21WAF1.
Therefore, the induction of p21WAF1 expression could
also occur in a p53-independent manner [20-22]. Once
activated, p21WAF1 exerts a negative effect on cell cycle
progression by preventing the CDK2/cyclin E complex
formation, leading to dephosphorylation (activation) of
Rb and, thereby, preventing E2F-mediated transcrip-
tional activation [21]. In addition to its role and cell
cycle progression, previous studies provided evidences
that p21WAF1 can trigger senescence either in a p53-
dependent and p53-independent manner [23].
In the present study, the effect of ABI3 expression on
cell senescence, coupled with inhibition of cell cycle
progression, up regulation of p21WAF1 and down regula-
tion of E2F1 expression, occurred in cancer cells in
which p53 function is disrupted [24]. Therefore, in our
model, p53 is unlikely to promote the ABI3-induced
p21WAF1expression.
Although further analysis is needed to identify the
underlying mechanism by which ABI3 induces p21WAF1
expression, our findings indicate that increase in
p21WAF1 may mediate cell cycle arrest and senescence
by blocking the CDk/Rb/E2F axis. It will be of interest
to assess the effect of ABI3 expression on total Rb levels
and its phosphorylation status.
In agreement with our findings, it was recently
demonstrated that the apoptotic effect of iodine, in
these cell lines, was mediated by mitochondrial pathway
that involved p21WAF1 accumulation in a p53-indepen-
dent mechanism. The authors suggested that p21WAF1 is
believe to be an important molecule in drug induced
tumor suppression, given that the block of p21WAF1 sig-
nificantly diminishes iodine-mediated apoptosis [25].
Up-regulation of p21WAF1 has been reported to enhance
apoptosis induced by antitumor agent in thyroid cancer
cells in a p53-independent manner [26].
Although we did not observe changes in AKT phos-
phorylation when ABI3 was re-expressed, our findings
corroborate with previous studies which demonstrated
that ABI3 re-expression had no effect on AKT phos-
phorylation in v-Src transformed NIH3T3 and U87 MG
cell lines [3].
In addition to increased growth rate, malignant trans-
formation requires the acquisition of a number of tumor
features. Although no significant differences were
observed in migration and invasion assays, here we
observed a direct correlation between ABI3 expression
and anchorage-independent growth. Additionally, ABI3
significantly decreased xenograft growth in mice.
Interestingly, it has been previously demonstrated that
ABI3 is a suppressive molecule in malignant cells [3].
The authors showed that ABI3 expression reduces cell
motility and metastatic dissemination of a highly meta-
static murine fibroblast transformed by v-Src (SRD) and
the human glioblastoma cell line (U87 MG), while it did
not interfere with cellular growth [3]. To examine mole-
cular mechanism underlying ABI3-mediated effects in
cell motility, the authors investigated whether the expres-
sion of Cdc42, Ras, Rac and Rho GTPases was affected
by ABI3 expression. Neither significant activation, nor
suppression was found in Cdc42, Rac, Ras and Rho.
Interestingly, a marked reduction in phosphorylation of
PAK2 was observed following expression of ABI3.
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Furthermore, the authors demonstrated that ABI3 and
PAK2 colocalized at the leading edge of the cells [3].
These findings corroborate with our hypothesis that
ABI3 loss could be common to other cancer types and
suggest that, similar to other ABI-family members [1],
ABI3 seems to function in a highly context-dependent
way. Additional studies will be required to verify
whether PAK2 and/or Rho and Rac small GTPases are
affected by ABI3 expression in other cancer subtypes
and to identify other mediator of cell motility.
In summary, our results indicate that ABI3 expression
plays an important role in suppressing tumor growth
and progression, given that its expression was signifi-
cantly lower in malignant specimens compared to
benign lesions and ectopic expression reduced the
transforming phenotype of both cell lines. The identifi-
cation of molecular events in the ABI3 pathway that
control processes such as senescence, migration and
invasion may suggest new therapeutic strategies for
cancer.
Conclusion
Our results indicate that ABI3 expression plays an
important role in the pathogenesis and the progression
of several cancers. A more detailed understanding of the
pathway by which ABI3 contribute to senescence may
lead to the development of novel agents that can sup-
press tumor development.
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